4.8 Article

Multicenter Prospective Validation of the Baveno IV and Baveno II/III Criteria in Cirrhosis Patients With Variceal Bleeding

Journal

HEPATOLOGY
Volume 61, Issue 3, Pages 1024-1032

Publisher

WILEY
DOI: 10.1002/hep.27407

Keywords

-

Funding

  1. Programme Hospitalier de Recherche Clinique (PHRC)

Ask authors/readers for more resources

The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted-blood-requirement-index (ABRI=number of blood units/(final-initial hematocrit+0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5-day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c-statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P=0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024-1032)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Georges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, Didier Samuel, Celine Dorival, Fabien Zoulim, Carole Cagnot, Thomas Decaens, Dominique Thabut, Tarik Asselah, Philippe Mathurin, Francois Habersetzer, Jean-Pierre Bronowicki, Dominique Guyader, Isabelle Rosa, Vincent Leroy, Olivier Chazouilleres, Victor de Ledinghen, Marc Bourliere, Xavier Causse, Paul Cales, Sophie Metivier, Veronique Loustaud-Ratti, Ghassan Riachi, Laurent Alric, Moana Gelu-Simeon, Anne Minello, Jerome Gournay, Claire Geist, Albert Tran, Armand Abergel, Isabelle Portal, Louis d'Alteroche, Francois Raffi, Helene Fontaine, Fabrice Carrat, Stanislas Pol

Summary: Treatment with direct antiviral agents is associated with reduced risk for mortality. The sustained virological response rate is 88%. Therefore, direct antiviral agents should be considered for any patient with HCV-related decompensated cirrhosis.

BMC INFECTIOUS DISEASES (2022)

Article Gastroenterology & Hepatology

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Isabelle Ollivier-Hourmand, Yohann Repesse, Pierre Nahon, Cendrine Chaffaut, Thong Dao, Thi Thu Nga Nguyen, Patrick Marcellin, Dominique Roulot, Victor De Ledinghen, Stanislas Pol, Dominique Guyader, Isabelle Archambeaud, Fabien Zoulim, Frederic Oberti, Albert Tran, Jean-Pierre Bronowicki, Louis D'Alteroche, Denis Ouzan, Jean-Marie Peron, Jean-Pierre Zarski, Marc Bourliere, Dominique Larrey, Alexandre Louvet, Paul Cales, Armand Abergel, Philippe Mathurin, Ariane Mallat, Jean-Frederic Blanc, Eric Nguyen-Khac, Ghassan Riachi, Laurent Alric, Lawrence Serfaty, Teresa Antonini, Christophe Moreno, Pierre Attali, Dominique Thabut, Christophe Pilette, Jean-Didier Grange, Christine Silvain, Nicolas Carbonell, Brigitte Bernard-Chabert, Odile Goria, Claire Wartelle, Romain Moirand, Christos Christidis, Gabriel Perlemuter, Violaine Ozenne, Jean Henrion, Sophie Hillaire, Vincent Di Martino, Xavier Amiot, Angela Sutton, Nathalie Barget, Sylvie Chevret, Nathalie Ganne-Carrie

Summary: The study indicates that non-O blood type does not influence the disease outcome, disease progression, or overall survival in Child-Pugh A cirrhotic patients.

LIVER INTERNATIONAL (2022)

Article Gastroenterology & Hepatology

The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO)

Oumarou Nabi, Jerome Boursier, Nathanael Lapidus, Philippe Mathurin, Victor de Ledinghen, Jean-Michel Petit, Marcel Goldberg, Marie Zins, Karine Lacombe, Lawrence Serfaty

Summary: This study evaluates the characteristics of non-alcoholic fatty liver disease (NAFLD) and its impact on morbidity and mortality in type 2 diabetic subjects in a community setting. The results show that diabetes significantly increases the risk of NAFLD and advanced fibrosis in diabetic patients. Furthermore, the presence of NAFLD in diabetic subjects is associated with an increased risk of severe liver-related events, cardiovascular disease, and overall mortality. The severity of fibrosis also correlates with an increased risk of hepatic and extrahepatic complications. These findings provide real-world evidence of the clinical and economic burden of NAFLD in diabetic subjects.

LIVER INTERNATIONAL (2022)

Correction Gastroenterology & Hepatology

The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study (vol 117, pg 301, 2022)

D. Morales-Arraez, M. Ventura-Cots, J. Altamirano, J. G. Abraldes, M. Cruz-Lemini, M. R. Thursz, S. R. Atkinson, S. K. Sarin, W. Kim, R. Chavez-Araujo, M. F. de la Tijera, A. K. Singal, V. H. Shah, P. S. Kamath, A. Duarte-Rojo, E. A. Charles, V. Vargas, M. Jager, P. E. Rautou, D. Rincon, F. Zamarripa, J. C. Restrepo-Gutierrez, A. Torre, M. R. Lucey, J. P. Arab, P. Mathurin, A. Louvet, G. Garcia-Tsao, J. A. Gonzalez, E. C. Verna, R. S. Brown, J. Argemi, C. Fernandez-Carrillo, A. Clemente, E. Alvarado-Tapias, E. Forrest, M. Allison, R. Bataller

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Article Gastroenterology & Hepatology

Lung Infection Affects Access to Treatment and Short-Term Outcome in Patients With Severe Alcohol-Related Hepatitis Treated With Corticosteroids

Line Carolle Ntandja Wandji, Massih Ningarhari, Elise Lemaitre, Marion Khaldi, Pierre Saffers, Julien Lollivier, Guillaume Lassailly, Sebastien Dharancy, Philippe Mathurin, Alexandre Louvet

Summary: Severe alcohol-related hepatitis patients with lung infection at admission had lower probability of receiving steroids compared to other infections and noninfected patients. Lung infection and nonresponse to steroids were independently associated with 3-month mortality after steroid initiation, highlighting the importance of specific management for lung infection during severe AH.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Letter Gastroenterology & Hepatology

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty

Francois Pattou, Guillaume Lasailly, Violeta Raverdy, Robert Caiazzo, Philippe Mathurin

HEPATOLOGY (2022)

Letter Gastroenterology & Hepatology

Reply

Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jerome Boursier, Philippe Mathurin, Celine Ribet, Victor de Ledinghen, Marie Zins, Marie-Aline Charles

HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors

Daniel Q. Huang, Philippe Mathurin, Helena Cortez-Pinto, Rohit Loomba

Summary: Global alcohol consumption has increased, leading to a rise in the incidence of alcohol-associated cirrhosis and hepatocellular carcinoma. Heavy alcohol consumption is a major cause of morbidity and mortality. Measures are needed to reduce the burden of alcohol-related liver diseases.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Surgery

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation

Kate Minoux, Guillaume Lassailly, Massih Ningarhari, Henri Lubret, Medhi El Amrani, Valerie Canva, Stephanie Truant, Philippe Mathurin, Alexandre Louvet, Gilles Lebuffe, Odile Goria, Eric Nguyen-Khac, Emmanuel Boleslawski, Sebastien Dharancy

Summary: This study investigated the trajectory of HCC patients awaiting liver transplantation who were treated with sorafenib. The results suggest that patients treated for HCC progression have high dropout rates and low survival rates, while patients treated for impossibility of loco-regional therapy have acceptable survival rates.

TRANSPLANT INTERNATIONAL (2022)

Article Gastroenterology & Hepatology

Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer-specific and overall mortality: A modeling approach

Massih Ningarhari, Abbas Mourad, Claire Delacote, Line-Carolle Ntandja Wandji, Guillaume Lassailly, Alexandre Louvet, Sebastien Dharancy, Philippe Mathurin, Sylvie Deuffic-Burban

Summary: This study evaluates the effects of hepatocellular carcinoma (HCC) screening on case fatality rates (CFRs) and cancer-specific mortality in patients with cirrhosis using a modeling approach. The results indicate that six-month ultrasound (US) screening can reduce the 10-year HCC-CFR, and shorter US intervals or the use of MRI can further decrease HCC-related mortality and overall mortality.

HEPATOLOGY COMMUNICATIONS (2022)

Letter Gastroenterology & Hepatology

Standardising early liver transplantation for severe alcohol-related hepatitis Reply

Philippe Mathurin, Sebastien Dharancy, Alexandre Louvet

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies

Claire Delacote, Line Carolle Ntandja Wandji, Alexandre Louvet, Pierre Bauvin, Guillaume Lassailly, Massih Ningarhari, Sebastien Dharancy, Philippe Mathurin, Sylvie Deuffic-Burban

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

A modelling approach to estimate alcohol-related liver morbidity and mortality in France

Claire Delacote, Line Carolle Ntandja Wandji, Alexandre Louvet, Pierre Bauvin, Guillaume Lassailly, Massih Ningarhari, Sebastien Dharancy, Guillaume Clement, Amelie Bruandet, Xavier Lenne, Philippe Mathurin, Sylvie Deuffic-Burban

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach

Massih Ningarhari, Abbas Mourad, Claire Delacote, Line Carolle Ntandja Wandji, Guillaume Lassailly, Alexandre Louvet, Sebastien Dharancy, Philippe Mathurin, Sylvie Deuffic-Burban

JOURNAL OF HEPATOLOGY (2022)

No Data Available